Truist Cuts Stryker Price Target as Wall Street Maintains Moderate Buy Consensus

Key Facts

1Truist cut its price target for Stryker Corp. from $380 to $330 while maintaining a Hold rating.

2The broader Wall Street consensus remains a 'Moderate Buy' with an average price target of $305.23.

Truist has lowered its price target for Stryker Corp. from $380 to $330 while maintaining a Hold rating on the stock. Despite this individual adjustment, the broader Wall Street consensus remains at a 'Moderate Buy' with an average price target of $305.23. This reflects a cautious but generally positive outlook on the company's position within the medical technology sector.

This target revision occurs as the healthcare sector navigates mixed pressures; for instance, peer Boston Scientific recently reported strong organic sales growth of 15% in its latest quarterly results according to public earnings data. Meanwhile, Zimmer Biomet (ZBH) is trading at lower valuation multiples compared to historical averages per market data, intensifying competition in the orthopedic implant market.

Investors will be watching for price stability following this cut, particularly after US Inflation (CPI) was reported at 3.8% YoY on May 12, 2026, according to economic calendar data. With no major corporate catalysts scheduled for the next seven days, market attention will likely remain on technical support levels near the consensus average of $305.23.